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OBJECTIVES The goal of this study was to investigate whether concomitant therapy with vasoactive
medications alters the results of noninvasive assessment of endothelial function.
BACKGROUND Ultrasound assessment of brachial artery flow-mediated dilation is emerging as a useful
clinical tool. The current practice of withholding cardiac medications before ultrasound
studies has unknown utility and would limit the clinical use of the methodology.
METHODS To determine whether a single dose of a vasoactive drug influences brachial reactivity, we
examined flow-mediated dilation and nitroglycerin-mediated dilation in 73 healthy subjects
(age 27  6 years). Studies were completed at baseline and 3 h after randomized treatment
with a single oral dose of placebo, felodipine (5 mg), metoprolol (50 mg), or enalapril (10 mg).
To determine if holding vasoactive therapy for 24 h before study yields different results than
continuation of clinically prescribed medications, we examined vascular function in 72
patients (age 57  10 years) with coronary artery disease. Ultrasound studies were performed
24 h after the last dose and again 3 h after patients took their clinically prescribed
medications.
RESULTS In healthy subjects one dose of all three drugs lowered blood pressure, and metoprolol also
lowered heart rate. However, there was no significant effect of treatment on brachial artery
dilation. In patients with coronary artery disease on chronic treatment, taking prescribed
medications reduced blood pressure and heart rate, but had no significant effect on brachial
artery dilation.
CONCLUSIONS Recent administration of commonly used nonnitrate vasoactive drugs has no significant effect
on brachial reactivity. These findings suggest that current practice of withholding cardiac
medications before testing endothelial function may not be necessary, making this method-
ology more practical for clinical use. (J Am Coll Cardiol 2002;40:761–5) © 2002 by the
American College of Cardiology Foundation
The vascular endothelium plays a critical role in the regu-
lation of vascular tone, inflammation, and thrombosis.
Impaired endothelial function in individuals with athero-
sclerosis and coronary risk factors contributes to the patho-
physiology of acute cardiovascular syndromes (1). Ultra-
sound examination of brachial artery flow-mediated dilation
(FMD) has emerged as a valuable noninvasive method for
assessing endothelial function and is developing into a
potentially useful tool in the clinical setting (2). Recent
studies in the coronary and forearm circulation demonstrate
that endothelial dysfunction is an independent predictor of
future cardiovascular events (3–7), highlighting the prog-
nostic importance of identifying abnormalities in vascular
function in individual patients. Noninvasive assessment of
endothelial function may prove valuable in cardiovascular
risk assessment and become a target for future cardiovascu-
lar risk reduction.
Although brachial artery reactivity appears promising, its
broad use has been limited by lack of standardized meth-
odology. The technique is highly operator dependent and
may vary according to technical factors such as arm cuff
position, image quality, method of analysis, and timing of
studies (8). One pressing methodological issue limiting the
clinical and research utility of this technique is the current
practice of withholding cardiac medications for at least 24 h
before study. Although the premise for this practice (remov-
ing confounding effects of vasoactive medications) makes
intuitive sense, there is little data to support it. Thus, the
purpose of this study was to investigate whether acute oral
administration of nonnitrate vasoactive agents commonly
used in clinical practice would have any influence on
brachial artery reactivity.
METHODS
Research subjects. We studied two groups of subjects.
One group consisted of normal healthy volunteers recruited
by advertisement who were excluded if they had a clinical
history of hyperlipidemia, diabetes mellitus, hypertension,
chest pain, claudication, prior stroke, or family history of
premature coronary artery disease (CAD). Subjects were
also excluded if they were pregnant, used tobacco, or were
taking any medications including antioxidant vitamins and
estrogen/progesterone supplements.
The second group included patients with angiographi-
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cally documented CAD (at least one coronary stenosis
50%). Exclusion criteria included unstable angina, uncon-
trolled hypertension, clinically significant valvular heart
disease, congestive heart failure, or any other condition that
would preclude safely withholding vasoactive medications as
required for the protocol. Written informed consent was
obtained, and the Institutional Review Board of Boston
Medical Center approved the protocol.
Study protocols. NORMAL SUBJECTS. After fasting over-
night, each subject rested quietly in a supine position for 15
min, and baseline vital signs were recorded. Blood pressure
was measured using an automated monitor (Dinamap XL,
Johnson and Johnson Medical, Arlington, Texas). Subjects
underwent baseline examination of endothelium-dependent
and -independent vasodilation of the brachial artery, as
previously described (9,10). Briefly, two-dimensional and
pulsed Doppler flow velocity signals were obtained from the
brachial artery at baseline and during reactive hyperemia
induced by 5-min arterial occlusion with a cuff on the upper
arm. The same arterial segment was imaged on all subse-
quent studies based on anatomical landmarks. After a
10-min rest period to allow restoration of baseline condi-
tions, brachial artery dilation was assessed before and 3 min
after administration of sublingual nitroglycerin (0.4 mg). If
the subject had a history of migraine headaches, systolic
blood pressure 100 mm Hg, or adverse reaction to
nitroglycerin, this portion of the protocol was omitted.
Brachial artery images were acquired using Toshiba 140
SSHA or Toshiba Powervision 6000 ultrasound systems
equipped with a 7.5-MHz transducer. Brachial images were
digitized at end diastole using an R-wave trigger. Personnel
blinded to both image sequence and treatment assignment
measured brachial arterial diameter and flow-velocity inte-
gral using customized software (9).
In a double-blind fashion, participants were consecutively
randomized to treatment with a single oral dose of placebo,
felodipine (5 mg), metoprolol (50 mg), or enalapril (10 mg).
Three hours after treatment, vital signs were recorded, and
brachial artery ultrasounds were repeated. A 3-h time point
was chosen because it represents a period within the window
for an acute physiologic drug effect based on known phar-
macokinetics of these medications.
SUBJECTS WITH CAD. Patients with CAD were asked to
withhold all vasoactive medications for 24 h, not smoke for
at least 24 h and to fast overnight before evaluation. After a
15-min supine rest period, baseline vital signs were recorded
and brachial artery studies performed as described above.
Subjects then took their usual morning antianginal and/or
antihypertensive medications as prescribed by their physi-
cians, except for oral or topical nitrates. Three hours after
treatment, vital signs were recorded and brachial artery
studies were repeated. Patient medications were recorded
and classified as beta-blocker, calcium channel blocker,
aspirin, or angiotensin-converting enzyme (ACE) inhibitor/
angiotensin receptor blocker.
Statistical analyses. In normal subjects the effects of treat-
ment on vascular function and hemodynamics were exam-
ined using two-way repeated measures analysis of variance
(ANOVA) with Student-Newman-Keuls post hoc compar-
ison. The two factors in this analysis were time (before and
after treatment) and drug (placebo, felodipine, metoprolol,
and enalapril) with brachial artery diameter, FMD,
nitroglycerin-mediated dilation (NMD), systolic and dia-
stolic blood pressure, and heart rate as dependent variables.
In patients with CAD, the effect of treatment on brachial
artery responses, vessel size, and hemodynamic parameters
were examined using the paired Student t tests.
To compare the effect of vasoactive medication adminis-
tration on the reproducibility of FMD in the normal
subjects, the absolute value of the difference between the
baseline and follow-up studies was calculated for each
treatment (placebo, felodipine, metoprolol, and enalapril)
and compared using one-way ANOVA. For subjects with
coronary disease, the absolute value of the difference be-
tween baseline and follow-up study was calculated and
compared with that observed in a prior study from our
laboratory (11) using the unpaired t test. All data are
presented as mean  SD unless otherwise indicated. A p
value 0.05 was considered significant. Statistical analysis
was performed with Sigma Stat for Windows 2.03 software
(SPSS Inc., Chicago, Illinois).
RESULTS
Clinical characteristics. A total of 145 subjects were stud-
ied. The group of normal healthy subjects (n  73) had
mean age 27  6 years, body mass index (BMI) 24  3
kg/m2 and were 66% male. The group of patients with
CAD (n  72) had mean age 57  10 years, BMI 30  7
kg/m2, and were 78% men. Of the patients with CAD, 64%
had a history of hypertension, 79% had hypercholesterol-
emia, 47% had a history of smoking, and 25% had a clinical
history of diabetes mellitus. The number and types of
medications taken by the patients with coronary disease are
displayed in Table 1.
Effects of single-dose treatment in healthy subjects. For
the entire group of normal subjects, mean baseline brachial
artery FMD was 9.5  5.3% and NMD 17.8  6.6%,
brachial artery diameter 3.8  0.7 mm, resting systolic
blood pressure 123  11 mm Hg, and heart rate 69  10
beats/min. Hemodynamics and brachial artery parameters
before and 3 h after treatment are shown in Table 2, and the
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANOVA  analysis of variance
BMI  body mass index
CAD  coronary artery disease
FMD  flow-mediated dilation
NMD  nitroglycerin-mediated dilation
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changes in these parameters are displayed in Figure 1. All
three classes of drugs significantly lowered systolic and mean
arterial pressure 3 h after treatment, and subjects who
received metoprolol experienced a significant reduction in
heart rate. Placebo had no significant effect on hemody-
namic or brachial artery parameters. The study had 80%
power (alpha  0.05) to detect a change of 2.4 percentage
points in FMD in any one group.
Effect of morning dose of vasoactive medication on
hemodynamics and vascular function. In contrast to nor-
mal subjects, patients with CAD had impaired brachial
artery dilator responses, consistent with previous studies
(10). For the entire group, baseline FMD was 7.5  4.4%
(p 0.016 compared with normal subjects), and NMD was
13.3  6.3% (p  0.002 compared with normal individu-
als). As shown in Table 3, blood pressure and heart rate
were significantly lower than baseline 3 h after the subjects
took their morning medications. In contrast, baseline diam-
eter, FMD and NMD were unaffected. The study had 80%
power (alpha  0.05) to detect a change of 1.2 percentage
points before and after medication treatment.
As shown in Table 1, 40% of patients were taking an
ACE inhibitor as part of their prescribed therapy. As for the
group as a whole, vascular function in this subgroup was
unaffected by treatment. Brachial artery FMD was 7.0 
4.3% at baseline and 6.9  4.5% 3 h later (p  0.91). In
individuals treated with the tissue-specific ACE inhibitor
quinapril (n 6), FMD was 6.9 6.5% at baseline and 6.4
 4.7% 3 h after the dose (p  0.64).
Effect of prescribed medications on reproducibility. To
investigate whether taking medication altered the reproduc-
ibility of FMD when measured twice over a 3-h period, we
compared the reproducibility of FMD in each group of
normal patients. The absolute value of the differences
between baseline and follow-up study were 2.9 1.7, 2.4
1.6, 2.4  2.3, and 2.7  2.6 percentage points, for the
placebo, felodipine, metoprolol, and enalapril groups, re-
spectively (p 0.84 by one-way ANOVA). For the patients
with coronary disease, we examined the reproducibility of
the baseline and follow-up study (with routine medications
administered between studies). This reproducibility was
compared with the reproducibility observed in a prior study
from our laboratory that involved a separate cohort of 43
patients with CAD and study of FMD before and 2 h after
administration of placebo (11). The absolute difference
between baseline and follow-up study was 2.5  2.5
percentage points in the present study and 2.1  2.8
percentage points in the prior study with placebo given
between studies (p  0.42). Thus, when vasoactive medi-
cations are administered between studies, reproducibility is
Table 1. Prescribed Medications in the Patients With Coronary
Artery Disease
Medication Type
Number of
Patients (%)
Total  72
ACE inhibitor 29 (40)
Angiotensin receptor antagonist 4 (6)
Beta-blocker 60 (83)
Calcium channel blocker 21 (29)
Aspirin 66 (92)
Taking medications from one class 3 (4)
Taking medications from two classes 34 (47)
Taking medications from three or more classes 35 (49)
ACE  angiotensin-converting enzyme.
Table 2. Hemodynamic and Brachial Parameters Before and After Drug Treatment in Healthy Subjects
Placebo (n  20) Felodipine (n  19) Metoprolol (n  20) Enalapril (n  14)
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2
SBP (mm Hg) 121  6 117  6 125  6 119  6* 123  6 113  6* 124  6 116  6*
DBP (mm Hg) 67  5 66  5 69  6 65  6* 69  6 67  6 71  5 65  5*
MAP (mm Hg) 85  5 83  5 88  5 83  5* 87  5 82  5* 89  4 82  4*
HR (beats/min) 67  7 67  7 68  7 71  7 74  7 65  7* 67  7 69  7
FMD (%) 10.6  2.2 11.6  2.2 8.6  2.2 9.4  2.2 8.3  2.2 9.0  2.2 10.9  2.2 11.5  2.2
NMD (%) 18.9  2.8 17.1  2.8 19.5  2.6 18.3  2.6 15.0  3.6 14  3.6 16.5  3.1 15  3.1
Brachial diameter (mm) 3.53  0.11 3.52  0.11 3.78  0.11 3.83  0.11 3.97  0.11 3.99  0.11 3.93  0.10 3.86  0.10
Reactive hyperemia (%) 501  276 634  276 751  278 552  278 723  278 664  278 823  279 730  279
*p  0.05 by repeated measures analysis of variance (baseline vs. 3 h, within each treatment group). Data are mean  SD.
DBP  diastolic blood pressure; FMD  flow-mediated dilation; HR  heart rate; MAP  mean arterial pressure; NMD  nitroglycerin-mediated dilation; SBP  systolic
blood pressure; Visit 1  baseline; Visit 2  3 h after treatment.
Figure 1. The effect of a single oral dose of vasoactive medication on
systolic blood pressure (SBP) (mm Hg) and absolute percent change in
brachial artery flow-mediated (FMD) and nitroglycerin-mediated dilation
(NMD) in normal subjects. Examinations were performed at baseline and
3 h after treatment with either placebo, felodipine (5 mg), metoprolol (50
mg), or enalapril (10 mg). *All three drugs lowered blood pressure
significantly (p  0.05) but had no effect on FMD or NMD. Open bar 
change in SBP (mm Hg); solid bar  change in FMD (%); hatched bar
 change in NMD (%).
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comparable with that observed when placebo is adminis-
tered between studies.
DISCUSSION
This study demonstrated that treatment with a single dose
of commonly used antihypertensive and antianginal medi-
cation lowers blood pressure and heart rate, but has no effect
on resting brachial artery size, FMD, NMD, and the
reproducibility of FMD. These results were obtained when
healthy patients received single doses of specific agents for
the first time and when patients on chronic therapy for
CAD are studied before and after receiving their clinically
prescribed medications. These findings suggest that acute
alterations in systemic hemodynamics and/or local resting
arterial tone induced by these medications do not alter the
capacity of the brachial artery to respond to endothelium-
derived and exogenous vasodilators.
No previous study examined the specific question ad-
dressed in the current study. In most prior studies of
endothelial function in human subjects, all vasoactive med-
ications were withheld for at least 24 h, and a recent paper
recommended withholding medications for four half-lives
(2) because of the concern that concurrent treatment would
confound the results. The present study raises the possibility
that this practice may not be necessary in some circum-
stances. While prescribed medications have been safely
withheld for 48 h in studies involving relatively large
numbers of patients with CAD (12) and for up to 14 days
in patients with hypertension (13), it certainly has a theo-
retical risk in patients with cardiovascular disease. When it
is not possible to closely monitor patients or make clinical
stability a criterion for eligibility (as was done in the present
study), the practice of withholding medications may be less
appropriate. For example, an ongoing study of endothelial
function in the Framingham Heart Study cohort does not
require that medications be withheld, although the large
sample size in that study will permit statistical adjustment
for medications (14). In spite of the present findings, it
remains likely that the study design of smaller scale and
intervention studies will continue to require that vasoactive
medications be withheld because of the possibility of inter-
actions between prescribed medications and the interven-
tion of interest.
The requirement to withhold vasoactive medications will
also be an important issue if assessment of endothelial
function proves to have clinical utility. There currently is
great interest in the possibility that the methodology will be
used to assess cardiovascular disease risk and to guide
therapy in individual patients (2). This interest is based on
the growing evidence that brachial endothelial function
provides independent prognostic information with regard to
future cardiovascular risk (4–7) and observations that many
interventions known to reduce cardiovascular risk also
improve endothelial function (15). If patients can undergo
testing of endothelial function without regard to their last
dose of vasoactive medication, the methodology will be
applicable to larger numbers of patients and clinical settings.
Several prior studies have demonstrated beneficial effects
of ACE inhibitors on endothelial function, and the negative
findings of the present study do not contradict that prior
work. For example, enalaprilat infusion acutely improves the
endothelium-dependent vasodilator response to acetylcho-
line in microvessels of the forearm (16) and the leg (17).
Several studies have shown improved FMD after more
chronic treatment with ACE inhibitors (18,19). It seems
likely that the failure to observe an effect of ACE inhibitors
in chronically treated patients in the present study indicates
that 24 h is an insufficient period of time for the beneficial
effects to subside. In support of this possibility is the
observation by Anderson et al. (18) that quinapril treatment
for eight weeks was associated with improved FMD com-
pared with baseline, even though the follow-up studies were
completed 72 h after the last dose of medication. Thus, a
longer washout period should be considered if a study
requires examination of endothelial function free from the
effects of ACE inhibitors.
Study limitations. There are several limitations of this
study. In patients with CAD, we did not examine the effects
of individual drugs on vascular reactivity but, rather, inves-
tigated the effect of all prescribed medications. We cannot
exclude the possibility that drug interactions masked an
effect of therapy to improve or worsen vasodilator function.
This possibility seems less likely given that we observed no
effect of the individual drugs in healthy subjects. Examining
the effect of all prescribed medications is more applicable to
the question of whether the methodology will have clinical
utility. The present study examined only a singe agent and
dose of the three classes of vasoactive medication. Thus, we
cannot exclude the possibility that other agents and/or
different doses might have had a different effect on vascular
function. Similarly, the effects of longer-term treatment
might have had a different effect.
Conclusions. Acute nonnitrate vasoactive drug therapy has
no effect on brachial artery vascular responses in healthy
subjects or in patients with CAD. These findings suggest
that it may not be necessary to hold vasoactive medications
Table 3. Brachial Responses and Hemodynamics After
Treatment in Patients With Coronary Artery Disease
Baseline
After
Treatment
p
Value
SBP (mm Hg) 134  18 128  20 0.001
DBP (mm Hg) 74  10 72  11 0.008
MAP (mm Hg) 94  12 90  13 0.001
HR (beats/min) 65  12 62  11 0.007
FMD (%) 7.5  4.4 7.6  4.8 0.97
NMD (%) 13.3  6.3 13.4  6.5 0.85
Brachial diameter (mm) 4.6  0.7 4.7  0.8 0.08
Reactive hyperemia (%) 585  379 623  304 0.68
Data are mean  SD.
Abbreviations as in Table 2.
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before ultrasound examination, making it more practical for
clinical use.
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